Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06519591
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-19
Brief Title:
Systemic Application of Cadonilimab LM-302 and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 182-positive Gastric Cancer With Peritoneal Metastasis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Systemic Application of Cadonilimab LM-302 and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 182-positive Gastric Cancer With Peritoneal Metastasis
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this phase 2 study we combined Cadonilimab LM-302 and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None